BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suárez-Zarracina T, Valle-Garay E, Collazos J, Montes AH, Cárcaba V, Carton JA, Asensi V. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. J Viral Hepat 2012;19:685-93. [PMID: 22967099 DOI: 10.1111/j.1365-2893.2012.01596.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Li Y, Zhang Y, Yin Y, Tu J, Xu Q, Liang H, Shen T. Impact of HIV-1 Infection on the Natural Progress of an Anti-HCV Positive Population in an Impoverished Village in China from 2009 to 2017. Viruses 2022;14:1621. [PMID: 35893687 DOI: 10.3390/v14081621] [Reference Citation Analysis]
2 Fisher BS, Fancher KA, Gustin AT, Fisher C, Wood MP, Gale M Jr, Burwitz BJ, Smedley J, Klatt NR, Derby N, Sodora DL. Liver Bacterial Dysbiosis With Non-Tuberculosis Mycobacteria Occurs in SIV-Infected Macaques and Persists During Antiretroviral Therapy. Front Immunol 2021;12:793842. [PMID: 35082782 DOI: 10.3389/fimmu.2021.793842] [Reference Citation Analysis]
3 Yang R, Gui X, Ke H, Xiong Y, Gao S. Combination antiretroviral therapy is associated with reduction in liver fibrosis scores in patients with HIV and HBV co-infection. AIDS Res Ther 2021;18:98. [PMID: 34924016 DOI: 10.1186/s12981-021-00419-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kirkegaard-Klitbo DM, Bendtsen F, Lundgren J, de Knegt RJ, Kofoed KF, Nielsen SD, Benfield T. Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls. J Infect Dis 2021;224:443-52. [PMID: 33320268 DOI: 10.1093/infdis/jiaa763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Dold L, Schwarze-Zander C, Boesecke C, Mohr R, Langhans B, Wasmuth JC, Strassburg CP, Rockstroh JK, Spengler U. Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA). Sci Rep 2019;9:12502. [PMID: 31467319 DOI: 10.1038/s41598-019-48756-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kim AY. Hepatitis B Virus and HIV Coinfection: Fibrosis, Fat, and Future Directions. Am J Gastroenterol 2019;114:710-2. [PMID: 30985299 DOI: 10.14309/ajg.0000000000000231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Newsum AM, Kooij KW, Boyd A, Smit C, Wit FWNM, van der Meer JTM, Prins M, Reiss P, van der Valk M; MOSAIC study group, ATHENA observational HIV cohort and NVHB-SHM hepatitis working group. Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM. AIDS 2019;33:833-44. [PMID: 30649050 DOI: 10.1097/QAD.0000000000002138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Yaya I, Marcellin F, Costa M, Morlat P, Protopopescu C, Pialoux G, Santos ME, Wittkop L, Esterle L, Gervais A, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13-HEPAVIH Cohort Study Group. Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS HEPAVIH CO-13 Cohort). Nutrients 2018;10:E705. [PMID: 29857547 DOI: 10.3390/nu10060705] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
9 Anadol E, Lust K, Boesecke C, Schwarze-Zander C, Mohr R, Wasmuth JC, Rockstroh JK, Trebicka J. Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients. PLoS One 2018;13:e0191118. [PMID: 29346443 DOI: 10.1371/journal.pone.0191118] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Collazos J, Valle-Garay E, Suárez-Zarracina T, Montes AH, Cartón JA, Asensi V. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. World J Virol 2017; 6(2): 36-45 [PMID: 28573088 DOI: 10.5501/wjv.v6.i2.36] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Kooij KW, Wit FW, van Zoest RA, Schouten J, Kootstra NA, van Vugt M, Prins M, Reiss P, van der Valk M; AGEhIV Cohort Study Group. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. AIDS 2016;30:1771-80. [PMID: 27088320 DOI: 10.1097/QAD.0000000000001119] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
12 Ryom L, Lundgren JD, De Wit S, Kovari H, Reiss P, Law M, El-Sadr W, Monforte AD, Mocroft A, Smith C, Fontas E, Dabis F, Phillips A, Sabin C; D:A:D Study Group. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS 2016;30:1731-43. [PMID: 26752282 DOI: 10.1097/QAD.0000000000001018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
13 Shuper PA, Joharchi N, Irving H, Fletcher D, Kovacs C, Loutfy M, Walmsley SL, Wong DK, Rehm J. Differential predictors of ART adherence among HIV-monoinfected versus HIV/HCV-coinfected individuals. AIDS Care 2016;28:954-62. [PMID: 26971360 DOI: 10.1080/09540121.2016.1158396] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
14 Collazos J, Valle-Garay E, Carton JA, Montes AH, Suarez-Zarracina T, De la Fuente B, Asensi V. Factors associated with long-term CD4 cell recovery in HIV-infected patients on successful antiretroviral therapy. HIV Med 2016;17:532-41. [PMID: 26754349 DOI: 10.1111/hiv.12354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Park LS, Hernández-Ramírez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS 2016;30:273-91. [PMID: 26691548 DOI: 10.1097/QAD.0000000000000922] [Cited by in Crossref: 118] [Cited by in F6Publishing: 125] [Article Influence: 16.9] [Reference Citation Analysis]
16 Arends JE, Lieveld FI, Boeijen LL, de Kanter CT, van Erpecum KJ, Salmon D, Hoepelman AI, Asselah T, Ustianowski A. Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms? J Hepatol 2015;63:1254-62. [PMID: 26186987 DOI: 10.1016/j.jhep.2015.06.034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
17 Collazos J, Asensi V, Martin G, Montes AH, Suárez-Zarracina T, Valle-Garay E. The effect of gender and genetic polymorphisms on matrix metalloprotease (MMP) and tissue inhibitor (TIMP) plasma levels in different infectious and non-infectious conditions. Clin Exp Immunol 2015;182:213-9. [PMID: 26206176 DOI: 10.1111/cei.12686] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
18 Leeming DJ, Anadol E, Schierwagen R, Karsdal MA, Byrjalsen I, Nielsen MJ, Schwarzer-Zander C, Boesecke C, Bendtsen F, Møller S, Strassburg CP, Spengler U, Krag A, Rockstroh J, Trebicka JK. Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. AIDS 2014;28:2081-90. [PMID: 25136933 DOI: 10.1097/QAD.0000000000000388] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
19 Avihingsanon A, Jitmitraparp S, Tangkijvanich P, Ramautarsing RA, Apornpong T, Jirajariyavej S, Putcharoen O, Treeprasertsuk S, Akkarathamrongsin S, Poovorawan Y, Matthews GV, Lange JM, Ruxrungtham K; HIV-NAT125 study team. Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. J Gastroenterol Hepatol 2014;29:1706-14. [PMID: 24730732 DOI: 10.1111/jgh.12613] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
20 Brescini L, Orsetti E, Gesuita R, Piraccini F, Marchionni E, Staffolani S, Castelli P, Drenaggi D, Barchiesi F. Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. Hepat Mon 2014;14:e15426. [PMID: 25337140 DOI: 10.5812/hepatmon.15426] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
21 Grint D, Peters L, Rockstroh JK, de Wit S, Mitsura VM, Knysz B, Pedersen C, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. AIDS 2014;28:577-87. [PMID: 24468998 DOI: 10.1097/QAD.0000000000000069] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
22 Kang W, Tong H, Sun Y, Lu Y. Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management. Expert Review of Gastroenterology & Hepatology 2014;8:247-66. [DOI: 10.1586/17474124.2014.876357] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
23 Allen J, Smith C, Bhagani S. Will antiretroviral therapy reduce HIV-related liver risk?: . Current Opinion in HIV and AIDS 2014;9:48-53. [DOI: 10.1097/coh.0000000000000022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]